Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus

Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes

(2020) Kenneth Cusi   DIABETES CARE

Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis

(2020) Rod S. Taylor et al.   GASTROENTEROLOGY

Mechanisms of Fibrosis Development in NASH

(2020) Robert F. Schwabe et al.   GASTROENTEROLOGY

MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease

(2020) Mohammed Eslam et al.   GASTROENTEROLOGY

NAFLD 2020: The State of the Disease

(2020) Thomas G. Cotter et al.   GASTROENTEROLOGY

Multicenter validation of association between decline in MRI‐PDFF and histologic response in nonalcoholic steatohepatitis

(2020) Rohit Loomba et al.   HEPATOLOGY

Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial

(2020) Keyur Patel et al.   HEPATOLOGY

NAFLD as a driver of chronic kidney disease

(2020) Christopher D. Byrne et al.   JOURNAL OF HEPATOLOGY

Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis–associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects

(2020) Mitsuhiro Kawakubo et al.   Scientific Reports

Leveraging the Gut to Treat Metabolic Disease

(2020) Ruth E. Gimeno et al.   Cell Metabolism

NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications

(2020) Giovanni Targher et al.   GUT

Nonalcoholic Steatohepatitis

(2020) Adam C. Sheka et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction

(2020) Ping An et al.   LIVER INTERNATIONAL

From NAFLD to MAFLD: when pathophysiology succeeds

(2020) Herbert Tilg et al.   Nature Reviews Gastroenterology & Hepatology

Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials

(2020) Olivia R Ghosh-Swaby et al.   Lancet Diabetes & Endocrinology

Deletion of Fructokinase in the Liver or in the Intestine Reveals Differential Effects on Sugar-Induced Metabolic Dysfunction

(2020) Ana Andres-Hernando et al.   Cell Metabolism

NAFLD and NASH in postmenopausal women: implications for diagnosis and treatment

(2020) Johanna K DiStefano   ENDOCRINOLOGY

Screening for Non-Alcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the U.S. is Cost Effective: A Comprehensive Cost-Utility Analysis

(2020) Mazen Noureddin et al.   GASTROENTEROLOGY

From NAFLD to MAFLD: Implications of a premature change in terminology

(2020) Zobair M Younossi et al.   HEPATOLOGY

Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials

(2020) Beth A. Davison et al.   JOURNAL OF HEPATOLOGY

Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial

(2020) Rohit Loomba et al.   Lancet Gastroenterology & Hepatology

Changing Trends in Liver Transplantation

(2020) Tommy Ivanics et al.   TRANSPLANTATION

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

(2020) Philip N. Newsome et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sex Differences in NAFLD : State of the Art and Identification of Research Gaps

(2019) Amedeo Lonardo et al.   HEPATOLOGY

NGM 282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis

(2019) Stephen A. Harrison et al.   HEPATOLOGY

The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients

(2019) Aino Latva-Rasku et al.   DIABETES CARE

Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts

(2019) Myriam Alexander et al.   BMC Medicine

The liver as an endocrine organ - linking NAFLD and insulin resistance

(2019) Matthew J Watt et al.   ENDOCRINE REVIEWS

Hepatocyte Deletion of Triglyceride‐Synthesis Enzyme DGAT 2 Reduces Steatosis without Increasing Inflammation or Fibrosis

(2019) Nina L. Gluchowski et al.   HEPATOLOGY

The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials

(2019) Arun J. Sanyal et al.   HEPATOLOGY

PS-110-Ketohexokinase inhibitor PF-06835919 administered for 6 weeks reduces whole liver fat as measured by magnetic resonance imaging-proton density fat fraction in subjects with non-alcoholic fatty liver disease

(2019) Roberto Calle et al.   JOURNAL OF HEPATOLOGY

LBP-20-VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial

(2019) Rohit Loomba et al.   JOURNAL OF HEPATOLOGY

PS-109-Partial inhibition of de novo lipogenesis with the acetyl-CoA carboxylase inhibitor PF-05221304 does not increase circulating triglycerides in humans and is sufficient to lower steatosis in rats

(2019) William Esler et al.   JOURNAL OF HEPATOLOGY

PS-106-An international, randomized, placebo-controlled phase 2 trial demonstrates novel effects of DGAT2 antisense inhibition in reducing steatosis without causing hypertriglyceridemia in T2DM patients

(2019) Rohit Loomba et al.   JOURNAL OF HEPATOLOGY

Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity

(2019) Philip Newsome et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

1681-P: Polyendocrinopathy in Type 1 Diabetes: A Transatlantic Comparison

(2019) JULIA HERMANN et al.   DIABETES

Epidemiology of chronic liver diseases in the USA in the past three decades

(2019) Zobair M Younossi et al.   GUT

Diabetes is Associated with Increased Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease

(2019) Ju Dong Yang et al.   HEPATOLOGY

The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis

(2019) Zobair M. Younossi et al.   JOURNAL OF HEPATOLOGY

Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD

(2019) Mary E. Rinella et al.   JOURNAL OF HEPATOLOGY

A liver-specific thyromimetic, VK2809, decreases hepatosteatosis in glycogen storage disease type Ia (GSD Ia)

(2019) Jin Zhou et al.   THYROID

Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial

(2019) Stefan Traussnigg et al.   Lancet Gastroenterology & Hepatology

Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial

(2019) Sabine Kahl et al.   DIABETES CARE

Glucagon-like peptide 1 (GLP-1)

(2019) T.D. Müller et al.   Molecular Metabolism

First‐in‐class fatty acid synthase inhibitor TVB‐2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities

(2019) Majid M. Syed‐Abdul et al.   HEPATOLOGY

Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence

(2019) Cheng et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study

(2019) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2019) Stephen A Harrison et al.   LANCET

Bile acids in glucose metabolism and insulin signalling — mechanisms and research needs

(2019) Tiara R. Ahmad et al.   Nature Reviews Endocrinology

Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Ceramides

(2019) Varman T. Samuel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease

(2019) Gordon I. Smith et al.   JOURNAL OF CLINICAL INVESTIGATION

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

Immune Responses in the Liver

(2018) Paul Kubes et al.   Annual Review of Immunology

Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases

(2018) Varman T. Samuel et al.   Cell Metabolism

Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis

(2018) Eric J. Lawitz et al.   Clinical Gastroenterology and Hepatology

Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis

(2018) Alessandro Mantovani et al.   DIABETES CARE

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

(2018) Mohammad Shafi Kuchay et al.   DIABETES CARE

Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with HALTHCC improves ablate and wait strategy

(2018) Daniel J. Firl et al.   HEPATOLOGY

Lipotoxicity and the gut-liver axis in NASH pathogenesis

(2018) Fabio Marra et al.   JOURNAL OF HEPATOLOGY

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2018) Stephen A Harrison et al.   LANCET

Direct effects of thyroid hormones on hepatic lipid metabolism

(2018) Rohit A. Sinha et al.   Nature Reviews Endocrinology

Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis

(2018) Kirstine S Tølbøl et al.   WORLD JOURNAL OF GASTROENTEROLOGY

A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis

(2018) Marina Kawaguchi-Suzuki et al.   Frontiers in Pharmacology

SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes

(2018) H.S. Bajaj et al.   DIABETES & METABOLISM

Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease

(2018) Masanori Shimizu et al.   DIABETES OBESITY & METABOLISM

Mechanisms of Insulin Action and Insulin Resistance

(2018) Max C. Petersen et al.   PHYSIOLOGICAL REVIEWS

Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes

(2018) Kenneth Cusi et al.   DIABETES OBESITY & METABOLISM

Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis

(2018) Rohit Loomba et al.   GASTROENTEROLOGY

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease

(2018) Rohit Loomba et al.   GASTROENTEROLOGY

Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis

(2018) Mary E. Rinella et al.   JOURNAL OF HEPATOLOGY

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

(2018) Arun Sanyal et al.   LANCET

Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

(2018) Edgar D. Charles et al.   Obesity

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study

(2018) Peter Ueda et al.   BMJ-British Medical Journal

Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice

(2017) Atsuo Tahara et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis

(2017) Kyle S. McCommis et al.   HEPATOLOGY

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids

(2017) Puneet Puri et al.   HEPATOLOGY

Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling

(2017) Samir Softic et al.   JOURNAL OF CLINICAL INVESTIGATION

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

(2017) Mukul R. Jain et al.   LIVER INTERNATIONAL

Global aetiology and epidemiology of type 2 diabetes mellitus and its complications

(2017) Yan Zheng et al.   Nature Reviews Endocrinology

Mechanisms of hepatic stellate cell activation

(2017) Takuma Tsuchida et al.   Nature Reviews Gastroenterology & Hepatology

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

(2017) Zobair Younossi et al.   Nature Reviews Gastroenterology & Hepatology

Insights into Stearoyl-CoA Desaturase-1 Regulation of Systemic Metabolism

(2017) Ahmed M. ALJohani et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial

(2017) Tisha R Joy et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis

(2017) Giovanni Musso et al.   JAMA Internal Medicine

Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis

(2016) E. Vilar-Gomez et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

(2016) Kenneth Cusi et al.   ANNALS OF INTERNAL MEDICINE

Hematopoietic-Derived Galectin-3 Causes Cellular and Systemic Insulin Resistance

(2016) Pingping Li et al.   CELL

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

(2016) Hiddo J.L. Heerspink et al.   CIRCULATION

Clinical Update: Cardiovascular Disease in Diabetes Mellitus

(2016) Cecilia C. Low Wang et al.   CIRCULATION

Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes

(2016) Romina Lomonaco et al.   DIABETES CARE

Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy

(2016) A. Dutour et al.   DIABETES OBESITY & METABOLISM

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

(2016) Vlad Ratziu et al.   GASTROENTEROLOGY

The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

(2016) Matthew J. Armstrong et al.   JOURNAL OF HEPATOLOGY

Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial

(2016) Jeffrey Cui et al.   JOURNAL OF HEPATOLOGY

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD

(2016) Barbara Gross et al.   Nature Reviews Endocrinology

Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats

(2016) Geraldine Harriman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Loss of Mitochondrial Pyruvate Carrier 2 in the Liver Leads to Defects in Gluconeogenesis and Compensation via Pyruvate-Alanine Cycling

(2015) Kyle S. McCommis et al.   Cell Metabolism

Adaptation of Hepatic Mitochondrial Function in Humans with Non-Alcoholic Fatty Liver Is Lost in Steatohepatitis

(2015) Chrysi Koliaki et al.   Cell Metabolism

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

(2015) Eduardo Vilar-Gomez et al.   GASTROENTEROLOGY

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

(2015) Paul Angulo et al.   GASTROENTEROLOGY

Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)

(2015) Rohit Loomba et al.   HEPATOLOGY

Nonalcoholic Fatty Liver Disease

(2015) Mary E. Rinella   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance

(2015) Sungsoon Fang et al.   NATURE MEDICINE

Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23

(2015) Chiara Degirolamo et al.   NATURE REVIEWS DRUG DISCOVERY

The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease

(2014) Rifaat Safadi et al.   Clinical Gastroenterology and Hepatology

A nontumorigenic variant of FGF19 treats cholestatic liver diseases

(2014) J. Luo et al.   Science Translational Medicine

Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study

(2014) Kathryn H. Williams et al.   Journal of Diabetes

Dual Peroxisome Proliferator-Activated Receptor  /  Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects

(2013) B. Cariou et al.   DIABETES CARE

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease

(2013) Jennifer E. Lambert et al.   GASTROENTEROLOGY

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

(2013) Bart Staels et al.   HEPATOLOGY

Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis

(2013) Ju Dong Yang et al.   HEPATOLOGY

Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT)—Relationship to Newly Identified Mitochondrial Pyruvate Carrier Proteins

(2013) Jerry R. Colca et al.   PLoS One

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program

(2012) M. J. Armstrong et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Long-Acting FGF21 Has Enhanced Efficacy in Diet-Induced Obese Mice and in Obese Rhesus Monkeys

(2012) Murielle M. Véniant et al.   ENDOCRINOLOGY

Nonalcoholic steatohepatitis versus steatosis: Adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism

(2012) Giovanni Musso et al.   HEPATOLOGY

A Mitochondrial Pyruvate Carrier Required for Pyruvate Uptake in Yeast, Drosophila, and Humans

(2012) D. K. Bricker et al.   SCIENCE

Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis

(2011) E. Boettcher et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Lowering Bile Acid Pool Size with a Synthetic Farnesoid X Receptor (FXR) Agonist Induces Obesity and Diabetes through Reduced Energy Expenditure

(2011) Mitsuhiro Watanabe et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes

(2011) M. Wu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State

(2010) f. M. Fisher et al.   DIABETES

Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis

(2010) N. Beraza et al.   GUT

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults

(2010) Elizabeth Selvin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance

(2009) A. O. Chavez et al.   DIABETES CARE

Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis

(2009) Koji Fujita et al.   HEPATOLOGY

Hepatic Stearoyl-CoA Desaturase (SCD)-1 Activity and Diacylglycerol but Not Ceramide Concentrations Are Increased in the Nonalcoholic Human Fatty Liver

(2008) A. Kotronen et al.   DIABETES

Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice

(2008) J. Xu et al.   DIABETES

Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial

(2008) Vlad Ratziu et al.   GASTROENTEROLOGY

Liver, Muscle, and Adipose Tissue Insulin Action Is Directly Related to Intrahepatic Triglyceride Content in Obese Subjects

(2008) Kevin M. Korenblat et al.   GASTROENTEROLOGY

Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist

(2008) Edward E. Cable et al.   HEPATOLOGY

Thematic Review Series: Glycerolipids.DGAT enzymes and triacylglycerol biosynthesis

(2008) Chi-Liang Eric Yen et al.   JOURNAL OF LIPID RESEARCH

Alterations in Adipose Tissue and Hepatic Lipid Kinetics in Obese Men and Women With Nonalcoholic Fatty Liver Disease

(2007) Elisa Fabbrini et al.   GASTROENTEROLOGY